Download PDF
Planta Med 2008; 74(13): 1644-1650
DOI: 10.1055/s-2008-1074553
Perspective
© Georg Thieme Verlag KG Stuttgart · New York

Mechanisms of Cancer Chemopreventive Agents: A Perspective

Jacquelyn Francy-Guilford1 , John M. Pezzuto1
  • 1College of Pharmacy, University of Hawaii at Hilo, Hilo, Hawaii, USA
Further Information

Publication History

Received: February 20, 2008 Revised: April 19, 2008

Accepted: April 22, 2008

Publication Date:
06 June 2008 (online)

   Permissions and Reprints

Abstract

A fundamental question addressed by drug development programs is how agents being tested function on a molecular level. Using resveratrol, curcumin and EGCG as examples, it is clear that a definitive mechanism of action for cancer chemopreventive agents is not available despite decades of exhaustive research. This is profoundly evident based on the myriad of biological responses that have been observed at the cellular level, and even more overwhelming when considering gene expression data that are now available. The situation is confounded further when chemopreventive agents are used in combination, even though superior clinical responses are anticipated. The best hope for delineating tangible, meaningful mechanisms resides in the use of complex physiological systems and computer models to decipher the most critical pathways that are appropriate for targeting with chemopreventive agents, their analogues, and combination treatments. Definitive answers concerning clinical efficacy are only available through human trials. Given the enormity of these tasks, together with the urgency of continuing the fight against cancer, it is adequate to move ahead with chemopreventive drug development on a semi-empirical basis, bearing in mind the importance of limiting toxic side effects.

Key words

Chemoprevention - Resveratrol - Curcumin - Epigallocatechin gallate - Microarrays - Systems biology

References

  • 1 Surveillance and Epidemiology and End Results (SEER) Cancer Statistics Review. 1975 – 2004 National Cancer Institute, National Institutes of Health
    Google Scholar
  • 2 Kelloff G J, Crowell J A, Steele V E, Lubet R A, Boone C W, Malone W A. et al . Progress in cancer chemoprevention.  Ann N Y Acad Sci. 1999;  889 1-13
    PubMedGoogle Scholar
  • 3 Fujiki H, Suganuma M, Imai K, Nakachi K. Green tea: cancer preventive beverage and/or drug.  Cancer Lett. 2002;  188 9-13
    CrossrefPubMedGoogle Scholar
  • 4 Surh Y J. Cancer chemoprevention with dietary phytochemicals.  Nat Rev Cancer. 2003;  3 768-80
    CrossrefPubMedGoogle Scholar
  • 5 Jang M, Cai L, Udeani G O, Slowing K V, Thomas C F, Beecher C W. et al . Cancer chemopreventive activity of resveratrol, a natural product derived from grapes.  Science. 1997;  275 218-20
    CrossrefPubMedGoogle Scholar
  • 6 Brakenhielm E, Cao R, Cao Y. Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes.  Faseb J. 2001;  15 1798-800
    PubMedGoogle Scholar
  • 7 Agarwal C, Sharma Y, Agarwal R. Anticarcinogenic effect of a polyphenolic fraction isolated from grape seeds in human prostate carcinoma DU145 cells: modulation of mitogenic signaling and cell-cycle regulators and induction of G1 arrest and apoptosis.  Mol Carcinogen. 2000;  28 129-38
    PubMedGoogle Scholar
  • 8 Pezzuto J M. Resveratrol as a cancer chemopreventive agent. In: Aggarwal BB, Shishodia S, editors. Resveratrol in health and disease.  New York: Marcel Dekker,. Inc;  2006 233-383
    PubMedGoogle Scholar
  • 9 Pezzuto J M. Resveratrol as an inhibitor of carcinogenesis. Pharm Biol 2008 46, in press
    Google Scholar
  • 10 Narayanan B A, Narayanan N K, Stoner G D, Bullock B P. Interactive gene expression pattern in prostate cancer cells exposed to phenolic antioxidants.  Life Sci. 2002;  70 1821-39
    CrossrefPubMedGoogle Scholar
  • 11 Yu R, Hebbar V, Kim D W, Mandlekar S, Pezzuto J M, Kong A N. Resveratrol inhibits phorbol ester and UV-induced activator protein 1 activation by interfering with mitogen-activated protein kinase pathways.  Mol Pharmacol. 2001;  60 217-24
    CrossrefPubMedGoogle Scholar
  • 12 Shishodia S, Chaturvedi M M, Aggarwal B B. Role of curcumin in cancer therapy.  Curr Probl Cancer. 2007;  31 243-305
    CrossrefPubMedGoogle Scholar
  • 13 Aggarwal B B, Kumar A, Bharti A C. Anticancer potential of curcumin: preclinical and clinical studies.  Anticancer Res. 2003;  23 363-98
    PubMedGoogle Scholar
  • 14 Shishodia S, Amin H M, Lai R, Aggarwal B B. Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma.  Biochem Pharmacol. 2005;  70 700-13
    CrossrefPubMedGoogle Scholar
  • 15 Narayan S. Curcumin, a multi-functional chemopreventive agent, blocks growth of colon cancer cells by targeting beta-catenin-mediated transactivation and cell-cell adhesion pathways.  J Mol Histol. 2004;  35 301-7
    PubMedGoogle Scholar
  • 16 Romiti N, Tongiani R, Cervelli F, Chieli E. Effects of curcumin on P-glycoprotein in primary cultures of rat hepatocytes.  Life Sci. 1998;  62 2349-58
    CrossrefPubMedGoogle Scholar
  • 17 Mukhopadhyay A, Banerjee S, Stafford L J, Xia C, Liu M, Aggarwal B B. Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation.  Oncogene. 2002;  21 8852-61
    CrossrefPubMedGoogle Scholar
  • 18 Anuchapreeda S, Leechanachai P, Smith M M, Ambudkar S V, Limtrakul P N. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells.  Biochem Pharmacol. 2002;  64 573-82
    CrossrefPubMedGoogle Scholar
  • 19 Chen A, Xu J, Johnson A C. Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1.  Oncogene. 2006;  25 278-87
    PubMedGoogle Scholar
  • 20 Huang T S, Lee S C, Lin J K. Suppression of c-Jun/AP-1 activation by an inhibitor of tumor promotion in mouse fibroblast cells.  Proc Natl Acad Sci U S A. 1991;  88 5292-6
    CrossrefPubMedGoogle Scholar
  • 21 Chun K S, Keum Y S, Han S S, Song Y S, Kim S H, Surh Y J. Curcumin inhibits phorbol ester-induced expression of cyclooxygenase-2 in mouse skin through suppression of extracellular signal-regulated kinase activity and NF-kappaB activation.  Carcinogenesis. 2003;  24 1515-24
    CrossrefPubMedGoogle Scholar
  • 22 Hussain A R, Al-Rasheed M, Manogaran P S, Al-Hussein K A, Platanias L C, Al Kuraya K. et al . Curcumin induces apoptosis via inhibition of PI3′-kinase/AKT pathway in acute T cell leukemias.  Apoptosis. 2006;  11 245-54
    CrossrefPubMedGoogle Scholar
  • 23 Marcu M G, Jung Y J, Lee S, Chung E J, Lee M J, Trepel J. et al . Curcumin is an inhibitor of p300 histone acetylatransferase.  Med Chem. 2006;  2 169-74
    CrossrefPubMedGoogle Scholar
  • 24 Han S S, Chung S T, Robertson D A, Ranjan D, Bondada S. Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, c-myc, bcl-XL, NF-kappa B, and p53.  Clin Immunol. 1999;  93 152-61
    CrossrefPubMedGoogle Scholar
  • 25 Korutla L, Cheung J Y, Mendelsohn J, Kumar R. Inhibition of ligand-induced activation of epidermal growth factor receptor tyrosine phosphorylation by curcumin.  Carcinogenesis. 1995;  16 1741-5
    CrossrefPubMedGoogle Scholar
  • 26 Takahashi M, Ishiko T, Kamohara H, Hidaka H, Ikeda O, Ogawa M. et al .Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) blocks the chemotaxis of neutrophils by inhibiting signal transduction through IL-8 receptors. Mediators Inflamm published online 28 June 2007: doi: 10.1155/2007/10 767
    Google Scholar
  • 27 Lin J K. Cancer chemoprevention by tea polyphenols through modulating signal transduction pathways.  Arch Pharm Res. 2002;  25 561-71
    PubMedGoogle Scholar
  • 28 Young J D, Lee E M. Inhibition of tumour invasion and angiogenesis by epigallocatechin gallate (EGCG), a major component of green tea.  Int J Exp Pathol. 2001;  82 309-16
    CrossrefPubMedGoogle Scholar
  • 29 Liang Y C, Lin-shiau S Y, Chen C F, Lin J K. Suppression of extracellular signals and cell proliferation through EGF receptor binding by (−)-epigallocatechin gallate in human A431 epidermoid carcinoma cells.  J Cell Biochem. 1997;  67 55-65
    CrossrefPubMedGoogle Scholar
  • 30 Lee S F, Liang Y C, Lin J K. Inhibition of 1,2,4-benzenetriol-generated active oxygen species and induction of phase II enzymes by green tea polyphenols.  Chem Biol Interact. 1995;  98 283-301
    PubMedGoogle Scholar
  • 31 Lin J K, Liang Y C, Lin-Shiau S Y. Cancer chemoprevention by tea polyphenols through mitotic signal transduction blockade.  Biochem Pharmacol. 1999;  58 911-5
    CrossrefPubMedGoogle Scholar
  • 32 Katiyar S K, Afaq F, Azizuddin K, Mukhtar H. Inhibition of UVB-induced oxidative stress-mediated phosphorylation of mitogen-activated protein kinase signaling pathways in cultured human epidermal keratinocytes by green tea polyphenol (−)-epigallocatechin-3-gallate.  Toxicol Appl Pharmacol. 2001;  176 110-7
    CrossrefPubMedGoogle Scholar
  • 33 Masuda M, Suzui M, Lim J T, Deguchi A, Soh J W, Weinstein I B. Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction.  J Exp Ther Oncol. 2002;  2 350-9
    CrossrefPubMedGoogle Scholar
  • 34 Nomura M, Kaji A, He Z, Ma W Y, Miyamoto K, Yang C S. et al . Inhibitory mechanisms of tea polyphenols on the ultraviolet B-activated phosphatidylinositol 3-kinase-dependent pathway.  J Biol Chem. 2001;  276 46 624-31
    PubMedGoogle Scholar
  • 35 Pianetti S, Guo S, Kavanagh K T, Sonenshein G E. Green tea polyphenol epigallocatechin-3 gallate inhibits Her-2/neu signaling, proliferation, and transformed phenotype of breast cancer cells.  Cancer Res. 2002;  62 652-5
    PubMedGoogle Scholar
  • 36 Ahmad N, Gupta S, Mukhtar H. Green tea polyphenol epigallocatechin-3-gallate differentially modulates nuclear factor kappaB in cancer cells versus normal cells.  Arch Biochem Biophys. 2000;  376 338-46
    CrossrefPubMedGoogle Scholar
  • 37 Narayanan B A, Narayanan N K, Re G G, Nixon D W. Differential expression of genes induced by resveratrol in LNCaP cells: P53-mediated molecular targets.  Int J Cancer. 2003;  104 204-12
    CrossrefPubMedGoogle Scholar
  • 38 Jones S B, DePrimo S E, Whitfield M L, Brooks J D. Resveratrol-induced gene expression profiles in human prostate cancer cells.  Cancer Epidemiol Biomarkers Prev. 2005;  14 596-604
    CrossrefPubMedGoogle Scholar
  • 39 Shi T, Liou L S, Sadhukhan P, Duan Z H, Novick A C, Hissong J G. et al . Effects of resveratrol on gene expression in renal cell carcinoma.  Cancer Biol Ther. 2004;  3 882-8
    PubMedGoogle Scholar
  • 40 Yang S H, Kim J S, Oh T J, Kim M S, Lee S W, Woo S K. et al . Genome-scale analysis of resveratrol-induced gene expression profile in human ovarian cancer cells using a cDNA microarray.  Int J Oncol. 2003;  22 741-50
    PubMedGoogle Scholar
  • 41 Park M J, Kim E H, Park I C, Lee H C, Woo S H, Lee J Y. et al . Curcumin inhibits cell cycle progression of immortalized human umbilical vein endothelial (ECV304) cells by up-regulating cyclin-dependent kinase inhibitor, p21WAF1/CIP1, p27KIP1 and p53.  Int J Oncol. 2002;  21 379-83
    PubMedGoogle Scholar
  • 42 Chen H W, Yu S L, Chen J J, Li H N, Lin Y C, Yao P L. et al . Anti-invasive gene expression profile of curcumin in lung adenocarcinoma based on a high throughput microarray analysis.  Mol Pharmacol. 2004;  65 99-110
    CrossrefPubMedGoogle Scholar
  • 43 Ramachandran C, Rodriguez S, Ramachandran R, Raveendran Nair P K, Fonseca H, Khatib Z. et al . Expression profiles of apoptotic genes induced by curcumin in human breast cancer and mammary epithelial cell lines.  Anticancer Res. 2005;  25 3293-302
    PubMedGoogle Scholar
  • 44 Wang S I, Mukhtar H. Gene expression profile in human prostate LNCaP cancer cells by (−)-epigallocatechin-3-gallate.  Cancer Lett. 2002;  182 43-51
    CrossrefPubMedGoogle Scholar
  • 45 Wyrick J J, Young R A. Deciphering gene expression regulatory networks.  Curr Opin Genet Dev. 2002;  12 130-6
    CrossrefPubMedGoogle Scholar
  • 46 Forrest A R, Taylor D F, Crowe M L, Chalk A M, Waddell N J, Kolle G. et al . Genome-wide review of transcriptional complexity in mouse protein kinases and phosphatases.  Genome Biol. 2006;  7 26
    CrossrefPubMedGoogle Scholar
  • 47 Reddy B S. Strategies for colon cancer prevention: combination of chemopreventive agents.  Subcell Biochem. 2007;  42 213-25
    PubMedGoogle Scholar
  • 48 Khafif A, Schantz S P, Chou T C, Edelstein D, Sacks P G. Quantitation of chemopreventive synergism between (−)-epigallocatechin-3-gallate and curcumin in normal, premalignant and malignant human oral epithelial cells.  Carcinogenesis. 1998;  19 419-24
    CrossrefPubMedGoogle Scholar
  • 49 Cruz-Correa M, Shoskes D A, Sanchez P, Zhao R, Hylind L M, Wexner S D. et al . Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis.  Clin Gastroenterol Hepatol. 2006;  4 1035-8
    CrossrefPubMedGoogle Scholar
  • 50 Hudson E A, Howells L M, Gallacher-Horley B, Fox L H, Gescher A, Manson M M. Growth-inhibitory effects of the chemopreventive agent indole-3-carbinol are increased in combination with the polyamine putrescine in the SW480 colon tumour cell line.  BMC Cancer. 2003;  3 2
    CrossrefPubMedGoogle Scholar
  • 51 Jacoby R F, Cole C E, Hawk E T, Lubet R A. Ursodeoxycholate/Sulindac combination treatment effectively prevents intestinal adenomas in a mouse model of polyposis.  Gastroenterology. 2004;  127 838-44
    CrossrefPubMedGoogle Scholar
  • 52 Ratko T A, Detrisac C J, Dinger N M, Thomas C F, Kelloff G J, Moon R C. Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats.  Cancer Res. 1989;  49 4472-6
    PubMedGoogle Scholar
  • 53 Rao C V, Tokumo K, Rigotty J, Zang E, Kelloff G, Reddy B S. Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, alpha-difluoromethylornithine, 16 alpha-fluoro-5-androsten-17-one, and ellagic acid individually and in combination.  Cancer Res. 1991;  51 4528-34
    PubMedGoogle Scholar
  • 54 Ip C, Ganther H E. Combination of blocking agents and suppressing agents in cancer prevention.  Carcinogenesis. 1991;  12 365-7
    CrossrefPubMedGoogle Scholar
  • 55 Bhuvaneswari V, Velmurugan B, Abraham S K, Nagini S. Tomato and garlic by gavage modulate 7,12-dimethylbenz[a]anthracene-induced genotoxicity and oxidative stress in mice.  Braz J Med Biol Res. 2004;  37 1029-34
    PubMedGoogle Scholar
  • 56 Velmurugan B, Nagini S. Combination chemoprevention of experimental gastric carcinogenesis by s-allylcysteine and lycopene: modulatory effects on glutathione redox cycle antioxidants.  J Med Food. 2005;  8 494-501
    PubMedGoogle Scholar
  • 57 Garewal H S. Beta-carotene and vitamin E in oral cancer prevention.  J Cell Biochem Suppl. 1993;  17F 262-9
    PubMedGoogle Scholar
  • 58 Bruggeman F J, Westerhoff H V. The nature of systems biology.  Trends Microbiol. 2007;  15 45-50
    CrossrefPubMedGoogle Scholar
  • 59 Ziegler R G, Colavito E A, Nartge P, McAdams M J, Schoenberg J B, Mason T J. et al . Importance of α-carotene, β-carotene, and other phytochemicals in the etiology of lung cancer.  J Natl Cancer Inst. 1996;  88 612-5
    CrossrefPubMedGoogle Scholar

Dr. John M. Pezzuto

College of Pharmacy

University of Hawaii at Hilo

60 Nowelo Street

Suite 101

Hilo

Hawaii 96720

USA

Phone: +1-808-443-5900

Fax: +1-808-443-5903

Email: pezzuto@hawaii.edu

      >